# Leniolisib for Immune Dysregulation in PIDs

> **NCT06549114** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pharming Technologies B.V.** · enrollment: 12 (estimated)

## Conditions studied

- Primary Immunodeficiency Disorders (PIDs)

## Interventions

- **DRUG:** Leniolisib

## Key facts

- **NCT ID:** NCT06549114
- **Lead sponsor:** Pharming Technologies B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-21
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06549114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06549114, "Leniolisib for Immune Dysregulation in PIDs". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06549114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*